Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 1101 to 1125 of 1146 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
455 decreased catalytic activity (GO:0003824) uroporphyrinogen decarboxylase (PR:000017134) 845: Inhibition, UROD
420 increased cell death (GO:0008219) urothelial cell (CL:0000731) 794: Increase, Cytotoxicity (urothelial cells)
421 increased cell proliferation (GO:0008283) urothelial cell (CL:0000731) 795: Increase, Regenerative cell proliferation (urothelial cells)
422 increased hyperplasia (MESH:D006965) urothelial cell (CL:0000731) 796: Increase, Hyperplasia (urothelial)
616 decreased rhythmic excitation (GO:0043179) vagus nerve (UBERON:0001759) 1220: Trigeminal nerve activation
337 increased musculoskeletal movement (GO:0050881) valve (UBERON:0003978) 1142: Increased, valve movement
498 decreased gene expression (GO:0010467) vascular endothelial growth factor A (PR:000017284) 948: reduced production, VEGF
696 decreased vascular endothelial growth factor A (PR:000017284) None
697 decreased abnormal protein level (MP:0008469) vascular endothelial growth factor A (PR:000017284) 948: reduced production, VEGF
218 decreased vascular endothelial growth factor receptor 2 binding (GO:0043184) vascular endothelial growth factor receptor 1 (PR:000007563) 305: Inhibition, VegfR2
217 decreased vascular endothelial growth factor receptor 2 binding (GO:0043184) vascular endothelial growth factor receptor 2 (PR:000002112) 305: Inhibition, VegfR2
600 increased vascular calcification (MESH:D061205) vasculature (UBERON:0002049) 1151: Osteoporosis and vascular calcification, Bone deterioration
958 increased Breast carcinoma (HP:0003002) VEGF-A complex (GO:1990150) 1376: Increase, angiogenesis
238 decreased secretion (GO:0046903) very-low-density lipoprotein (CHEBI:39027) 450: Decrease, Very low-density lipoprotein export capacity
932 occurrence membrane fusion (GO:0061025) vesicle membrane (GO:0012506) 2159: Influenza A virus (IAV) cell entry
761 increased viral RNA genome packaging (GO:0019074) viral assembly compartment (GO:0072516) 1847: Increased SARS-CoV-2 production
908 occurrence viral entry into host cell (GO:0046718) viral genome (GO:0019015) 1738: SARS-CoV-2 cell entry
934 occurrence toll-like receptor 3 signaling pathway (GO:0034138) viral genome (GO:0019015) None
935 occurrence toll-like receptor 7 signaling pathway (GO:0034154) viral genome (GO:0019015) None
936 decreased toll-like receptor 3 signaling pathway (GO:0034138) viral genome (GO:0019015) None
950 occurrence nuclear export (GO:0051168) viral genome (GO:0019015) None
577 increased Viral load (MESH:D019562) 1109: Increased, Deformed Wing Virus levels
909 occurrence viral entry into host cell (GO:0046718) viral protein (PR:000036197) 1738: SARS-CoV-2 cell entry
756 increased viral RNA genome replication (GO:0039694) viral RNA-directed RNA polymerase complex (GO:0031381) 1847: Increased SARS-CoV-2 production
757 increased positive stranded viral RNA replication (GO:0039690) viral RNA-directed RNA polymerase complex (GO:0031381) 1847: Increased SARS-CoV-2 production